“SFJ has proven to be a collaborative and transparent partner from the start of our partnership. Their team is extremely knowledgeable, and add immense value well beyond the financial aspect. SFJ has remained a committed partner as we have navigated the regulatory process, with a success-driven mindset.”
— Cedric Francois, CEO
“Working with the SFJ team to design the optimal structure for Apellis was a truly collaborative effort. Together we structured a deal that was honestly transformational for Apellis and a true success for SFJ. They were creative, balancing their obligations with our needs and working with them was a pleasure. I would highly recommend.”
— Tim Sullivan, CFO
Apellis, a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals.
PhaseBio, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, announced a financing and co-development collaboration with SFJ to support the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor.
Nektar Therapeutics, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG).